Waystar Weighs Sale as Software Sector Faces Market Pressure

Healthcare software provider Waystar is reportedly exploring strategic alternatives, including a potential sale, according to several sources familiar with the situation. This move comes just two years after the company went public in New York, and as its market valuation faces significant pressure.

Investment Bank Advises on Potential Sale

Waystar, known for its technology that automates administrative tasks for hospitals and doctors, has enlisted investment bank Evercore to guide the process. Two sources, who requested anonymity, indicated that these discussions are still in the preliminary stages. While a sale is one option on the table, they cautioned that plans could shift and a deal may not occur.

The company's market value has declined to approximately $4.8 billion following a 24% drop in share price this year, amid a broader downturn in the software sector. The current auction process seeks to evaluate investor interest in software companies despite these market conditions.

Market Dynamics and Investor Sentiment

Waystar has positioned itself as a healthcare software firm, rather than a services company, in an effort to attract higher valuations typical of tech companies. Initially, this strategy was successful, with shares climbing from $20 to a peak of $45 in 2025. However, concerns over potential disruptions from advances in artificial intelligence have since placed downward pressure on the stock.

The company was created through the 2017 merger of Zirmed and Navicure, both leaders in healthcare revenue management. Major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who took Waystar public in 2024. EQT remains the largest shareholder with a 13% stake, followed by CPPIB at 10% and BlackRock at 8%, according to LSEG data.

Stakeholder Responses and Future Prospects

In response to inquiries, Waystar, Evercore, EQT, CPPIB, and BlackRock have declined to comment on the ongoing situation. As the software sector continues to grapple with market volatility, the outcome of Waystar's exploration of strategic options remains uncertain.

This development underscores the challenges faced by software companies in maintaining investor confidence amidst technological advancements and market fluctuations. The potential sale of Waystar will be closely monitored as it may signal broader trends within the healthcare technology landscape.